Célia Jacoberger Foissac (Celia Jacoberger-Foissac, Célia Jacoberger-Foissac)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Regulatory T Cells

Klebsiella Pneumoniae

Sentinel Lymph Node

Top Venues

Science translational medicine

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Michael C Warren, Stephan Matissek, Matthew P Rausch, Marisella Panduro, R J Hall, Austin Dulak, David Brennan, Sonia Das Yekkirala, Secil Koseoglu, Ricard Masia, Yu Yang, Navamallika Reddy, Robert Prenovitz, Jamie Strand, Tauqueer Zaidi, Erik Devereaux, Célia Jacoberger Foissac, John Stagg, Benjamin H Lee, Pamela Holland, Vito J Palombella, Andrew C Lake
SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties. ImmunoHorizons 7 (5) (2023)
Paulien Kaptein, Célia Jacoberger Foissac, Petros Dimitriadis, Paula Voabil, Marjolein de Bruijn, Simone Brokamp, Irene Reijers, Judith M Versluis, Gahyathiri Nallan, Hannah Triscott, Elizabeth McDonald, Joshua Tay, Georgina V Long, Christian U Blank, Daniela S Thommen, Michele W L Teng
Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors. Science translational medicine 14 (642) (2022)
Célia Jacoberger Foissac, Isabelle Cousineau, Yacine Bareche, David Allard, Pavel Chrobak, Bertrand Allard, Sandra Pommey, Nouredin Messaoudi, Yannic McNicoll, Geneviève Soucy, Secil Koseoglu, Ricard Masia, Andrew C Lake, Heewon Seo, Christopher B Eeles, Neha Rohatgi, Simon C Robson, Simon Turcotte, Benjamin Haibe-Kains, John Stagg
CD73 inhibits cGAS-STING and cooperates with CD39 to promote pancreatic cancer. Cancer immunology research (2022)